Medical Condition News

RSS

CAN DO Houston expands childhood obesity initiative with major grant

CAN DO Houston (Children and Neighbors Defeating Obesity) will expand its community-based efforts with a $360,000 grant from the Robert Wood Johnson Foundation's "Healthy Kids, Healthy Communities" initiative.

13 Jan 2010

New analysis finds cost of diabetes and pre-diabetes reached $218 billion in 2007

A new analysis found that the cost of diabetes and pre-diabetes reached $218 billion in 2007, with the exploding number of cases of type 2 diabetes responsible for the majority of the costs. The National Changing Diabetes® Program (NCDP), a program of Novo Nordisk, commissioned the analysis, published online as a Web First article today in Health Affairs and performed by researchers at The Lewin Group.

13 Jan 2010

Research shows missing, mutated genes occur simultaneously in unique set of pediatric brain tumors

Brain cancer is the leading cause of cancer death in children. Now a more accurate diagnosis of childhood brain cancers may soon be possible, according to researchers at Huntsman Cancer Institute (HCI) at the University of Utah. The information is published online today in the journal Cancer Research.

13 Jan 2010

Olfactory dysfunction may serve as an early diagnostic tool for Alzheimer's disease

A study published in the January 13, 2010 issue of the Journal of Neuroscience links a loss of smell function in Alzheimer's disease (AD) model animals with amyloid β (protein) accumulation in the brain, a distinguishing hallmark of Alzheimer's disease. Research conducted by NYU Langone Medical Center suggests that olfactory dysfunction, a common symptom of AD, may serve as an early diagnostic tool for the disease.

13 Jan 2010

Emisphere Technologies: Novo Nordisk initiates first Phase I clinical trial of GLP-1

Emisphere Technologies, Inc. today announced that Novo Nordisk has initiated its first Phase I clinical trial with a long-acting oral GLP-1 analogue (NN9924). This milestone releases a $2 million payment to Emisphere, whose proprietary Eligen® Technology is used in the formulation of NN9924.

13 Jan 2010

Study: Patients with specific oncogenic rearrangements of ALK gene show greater response to new therapy

Results of a new study in non-small cell lung cancer showed that patients with specific oncogenic rearrangements of the anaplastic lymphoma kinase (ALK) gene within the short arm of chromosome 2 of their tumors had a much greater response to a new therapy - an ALK-inhibitor.

13 Jan 2010

Extended treatment with active ingredient increases bone volume and calcium content

Genta Incorporated today announced publication of two scientific studies that test the active ingredient in Genta’s program to develop orally available gallium-containing compounds and the Company’s marketed product, Ganite® (gallium nitrate for injection).

13 Jan 2010

Retreating with gefitinib may benefit non-small cell lung cancer patients

Patients with non-small cell lung cancer in whom treatment with gefitinib is ineffective often have limited options, but results of a new study suggest that retreating patients with the same drug could have a beneficial effect.

13 Jan 2010

University of Leicester study provides new insights into preventer and reliever treatments for asthma

A new study at the University of Leicester is probing why asthma relief inhalers might actually make asthma worse- and what can be done about it.

13 Jan 2010

Three tumor microRNAs may help identify chemoresistance in small cell lung cancer patients

At least three tumor microRNAs appear to predict when first-line chemotherapy will prove ineffective in some patients with small cell lung cancer, according to data presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, held Jan. 11-14, 2010.

13 Jan 2010

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.

13 Jan 2010

NexMed's NexACT technology enhances Taxol's bioavailability through oral administration

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from its research and development group at Bio-Quant successfully demonstrated the ability of the NexACT technology to deliver an oral formulation of Taxol® (paclitaxel) and to enhance the drug’s bioavailability by approximately ten-fold through this oral administration. Taxol, a first line chemotherapy drug used to treat breast, lung and ovarian cancers, is currently administered through an intravenous infusion that can take up to 24 hours to complete.

13 Jan 2010

PRP injections are ineffective for treating Achilles tendon disorder

An apparently increasingly used treatment method for a type of Achilles tendon disorder that includes injection of platelet-rich plasma into the tendon does not appear to result in greater improvement in pain or activity compared to placebo, according to results of a preliminary study published in the January 13 issue of JAMA.

13 Jan 2010

RWJF awards multi-year grants to 41 communities to reverse childhood obesity epidemic by 2015

The Robert Wood Johnson Foundation (RWJF) has awarded multi-year grants to 41 communities across the country as part of a landmark national program to reverse the childhood obesity epidemic by 2015.

13 Jan 2010

First sulfite-free rectal suspension for UC

sfRowasa™ (mesalamine) Rectal Suspension 4g/60mL –Sulfite-Free Formulation, is the first sulfite-free rectal suspension available for Ulcerative colitis (UC). According to a study published in The American Journal of Gastroenterology, products containing sulfites may exacerbate natural sulfide levels in the colon and may increase inflammation in UC patients. With its sulfite-free preparation, sfRowasa™ offers a new treatment option for the treatment of active, mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis.

13 Jan 2010

Green tea could modulate smoke-induced lung cancer

Drinking green tea could modulate the effect of smoking on lung cancer. Results of this hospital-based, randomized study conducted in Taiwan were presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, held here from Jan. 11-14, 2010.

13 Jan 2010

New clinical study: CeNeRx BioPharma's CXB722 has potential as novel anxiolytic

CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today reported that a new clinical study shows that its investigational compound CXB722 has potential as a novel anxiolytic, demonstrating a significant effect on both endocrine and cardiovascular biomarkers associated with stress.

13 Jan 2010

LUMEN 2010 analyzes strategies to reduce rising mortality in women with cardiovascular disease

It is no longer a theory. Percutaneous coronary intervention (PCI) or coronary angioplasty is the best treatment for a person presenting with STEMI (ST- elevation myocardial infarction), a heart attack caused by complete obstruction of a coronary artery.

13 Jan 2010

BARDA invites Aeolus Pharmaceuticals to submit proposal for development of AEOL 10150

Aeolus Pharmaceuticals, Inc. announced today that after review of the Company’s white paper on development of AEOL-10150 as a countermeasure for the lung effects of acute radiation syndrome, the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Radiological and Nuclear (CBRN) Countermeasures has informed the Company that, after careful analysis and consideration, it has invited Aeolus to submit a full proposal for a contract to develop AEOL 10150 from its current level of technical readiness to FDA approval.

13 Jan 2010

Studies show naturally-occurring protein in humans restores motor function in rats after a stroke

People with impaired mobility after a stroke soon may have a therapy that restores limb function long after the injury, if a supplemental protein works as well in humans as it does in paralyzed rats.

13 Jan 2010

Medical Condition News

CAN DO Houston expands childhood obesity initiative with major grant

New analysis finds cost of diabetes and pre-diabetes reached $218 billion in 2007

Research shows missing, mutated genes occur simultaneously in unique set of pediatric brain tumors

Olfactory dysfunction may serve as an early diagnostic tool for Alzheimer's disease

Emisphere Technologies: Novo Nordisk initiates first Phase I clinical trial of GLP-1

Study: Patients with specific oncogenic rearrangements of ALK gene show greater response to new therapy

Extended treatment with active ingredient increases bone volume and calcium content

Retreating with gefitinib may benefit non-small cell lung cancer patients

University of Leicester study provides new insights into preventer and reliever treatments for asthma

Three tumor microRNAs may help identify chemoresistance in small cell lung cancer patients

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

NexMed's NexACT technology enhances Taxol's bioavailability through oral administration

PRP injections are ineffective for treating Achilles tendon disorder

RWJF awards multi-year grants to 41 communities to reverse childhood obesity epidemic by 2015

First sulfite-free rectal suspension for UC

Green tea could modulate smoke-induced lung cancer

New clinical study: CeNeRx BioPharma's CXB722 has potential as novel anxiolytic

LUMEN 2010 analyzes strategies to reduce rising mortality in women with cardiovascular disease

BARDA invites Aeolus Pharmaceuticals to submit proposal for development of AEOL 10150

Studies show naturally-occurring protein in humans restores motor function in rats after a stroke

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News